Psoriasis

Patients who had an “intermediate” response to adalimumab saw improvements to markers of psoriasis and quality of life after switching to risankizumab, according to results from a phase 3 trial presented at Maui Derm for Dermatologists.

Depression rates were lower in patients treated with apremilast monotherapy for psoriasis or psoriatic arthritis and higher in those treated with biologics, corticosteroids and non-apremilast combinations, according to a presentation.

The National Psoriasis Foundation’s COVID-19 task force has updated its guidelines for managing psoriatic disease during the pandemic.

Higher systemic inflammation and cardiovascular risk factors were identified in individuals with psoriasis and metabolic syndrome, according to a study published in Journal of the American Academy of Dermatology.

An investigational new drug program has been approved by the FDA for oral orismilast for the treatment of plaque psoriasis, Union Therapeutics announced in a press release.

Healio launched Healio Psoriatic Disease in 2020, a publication dedicated to the coverage of psoriasis and psoriatic disease.

Shared decision-making involves considering patients’ preferences and values in cooperation with health care professionals before making treatment decisions.

Acitretin, apremilast and methotrexate can be used to treat immune checkpoint inhibitors-mediated psoriasis, according to a study published in Journal of the American Academy of Dermatology.

Clinicians treating pregnant women who have psoriasis have limited data to guide treatment decisions, according to a review.

Dermatologists are often the only health care professional patients with chronic skin conditions see, according to a study published in Journal of the American Academy of Dermatology.